# Post-Gastric Bypass Hypoglycemia



ClinicalTrials.gov Identifier: NCT01933490

Recruitment Status : Completed
First Posted : September 2, 2013
Last Update Posted : November 1, 2019



**Sponsor:**
University of Minnesota

**Information provided by (Responsible Party):**
University of Minnesota



## Study Description



Brief Summary:

Post-gastric bypass hyperinsulinemic hypoglycemia is a recently described disorder occurring in some patients after gastric bypass surgery for obesity. The pathogenesis is incompletely understood but involves a robust insulin response to ingested carbohydrate. The resultant hyperinsulinemia sometimes produces hypoglycemia with neuroglycopenia,

confusion and even loss of consciousness. Various treatments have been recommended including low carbohydrate diets, coingestion of the medication acarbose with carbohydrate containing meals, partial pancreatectomy and even total pancreatectomy. None is completely satisfactory. We propose to test two new potential treatments. Using a design with random assignment of three conditions we plan to compare, in 10 patients with post-gastric bypass hyperinsulinemic hypoglycemia, a high carbohydrate test meal (control condition), a high carbohydrate test meal after pre-treatment with rapid acting aspart insulin (insulin condition), and a high fructose, low glucose test meal with carbohydrate and caloric content similar to the control meal (fructose condition).

| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hyperinsulinemic Hypoglycemia | Other: high carbohydrate test meal<br>Other: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin<br>Other: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal | Not Applicable |

Detailed Description:

Post-gastric bypass hyperinsulinemic hypoglycemia is a recently described disorder occurring in some patients after gastric bypass surgery for obesity. The pathogenesis is incompletely understood but involves a robust insulin response to ingested carbohydrate. The resultant hyperinsulinemia sometimes produces hypoglycemia with neuroglycopenia, confusion and even loss of consciousness. Various treatments have been recommended including low carbohydrate diets, coingestion of the medication acarbose with carbohydrate containing meals, partial pancreatectomy and even total pancreatectomy. None is completely satisfactory. We propose to test two new potential treatments. Using a design with random assignment of three conditions we plan to compare, in 10 patients with post-gastric bypass hyperinsulinemic hypoglycemia, a high carbohydrate test meal (control condition), a high carbohydrate test meal after pre-treatment with rapid acting aspart insulin (insulin condition), and a high fructose, low glucose test meal with carbohydrate and caloric content similar to the control meal (fructose condition). The hypothesis to be tested are 1) pretreatment with aspart insulin will prevent, or at least reduce, the occurrence of hypoglycemia and 2) substitution of fructose for glucose in the test meal will prevent, or at least reduce, the occurrence of hypoglycemia. Plasma glucose and serum insulin will be sampled before and for four hours after the three test conditions. The primary study endpoint will be the occurrence or not of plasma glucose < 60 mg/dL after the test meals. The control meal will be compared to the insulin pre-treated test meal and, in a separate comparison, to the fructose test meal. Secondary endpoints will be comparisons between the control and active treatments in peak postprandial serum insulin, peak postprandial plasma glucose, nadir postprandial plasma glucose, and the 4-hr longitudinal course of plasma glucose measurements.

## Study Design

Go to

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment

| | |
|---|---|
| Masking: | None (Open Label) |
| Primary Purpose: | Health Services Research |
| Official Title: | Prevention of Hypoglycemia in Patients With Post-Gastric Bypass Hyperinsulinemic Hypoglycemia |
| Study Start Date : | August 2013 |
| Actual Primary Completion Date : | August 2014 |
| Actual Study Completion Date : | August 2014 |

**Resource links provided by the National Library of Medicine**

MedlinePlus Genetics related topics: Congenital hyperinsulinism

MedlinePlus related topics: Hypoglycemia

Genetic and Rare Diseases Information Center resources: Congenital Hyperinsulinism

U.S. FDA Resources

## Arms and Interventions

Go to

| Arm | Intervention/treatment |
|---|---|
| a high carbohydrate test meal (control condition)<br>a high carbohydrate test meal (control condition) | Other: high carbohydrate test meal<br>Other: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin<br>Other: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal |
| Active Comparator: high carbohydrate test meal after pre-treatment<br>a high carbohydrate test meal after pre-treatment with rapid acting aspart insulin (insulin condition) | Other: high carbohydrate test meal<br>Other: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin<br>Other: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal |
| Active Comparator: high fructose low glucose test meal<br>high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal (fructose condition) | Other: high carbohydrate test meal<br>Other: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin<br>Other: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal |

## Outcome Measures

Go to

Primary Outcome Measures :

1. The primary study endpoint will be occurrence or not of plasma glucose < 60 mg/dL during the 4 hours after the test meal (binary endpoint). [ Time Frame: 4 hours after meal ]

   The primary study endpoint will be occurrence or not of plasma glucose < 60 mg/dL during the 4 hours after the test meal (binary endpoint).

## Eligibility Criteria

Go to

**Information from the National Library of Medicine**

*Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.*

| | |
|---|---|
| Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |

**Criteria**

Inclusion Criteria:

- Participants must be at least 21 years of age
- History of postprandial hypoglycemia with neuroglycopenia occurring one year or more after gastric bypass surgery
- History of spontaneous correction of hypoglycemia
- Normal fasting plasma glucose and serum insulin after a carbohydrate containing mixed meal, demonstration of serum insulin > 50u/UL and plasma glucose < 50mg/dL

Exclusion Criteria:

- Under 21 years of age

## Contacts and Locations

Go to

**Information from the National Library of Medicine**

*To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.*

*Please refer to this study by its ClinicalTrials.gov identifier (NCT number):*
***NCT01933490***

### Locations

**United States, Minnesota**

University of Minnesota
Minneapolis, Minnesota, United States, 55455

### Sponsors and Collaborators

University of Minnesota

### Investigators

Principal Investigator: John Bantle, MD University of Minnesota

## More Information

Go to

**Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):**

Bantle AE, Wang Q, Bantle JP. Post-Gastric Bypass Hyperinsulinemic Hypoglycemia: Fructose is a Carbohydrate Which Can Be Safely Consumed. J Clin Endocrinol Metab. 2015 Aug;100(8):3097-102. doi: 10.1210/jc.2015-1283. Epub 2015 Jun 2.

| | |
|---|---|
| Responsible Party: | University of Minnesota |
| ClinicalTrials.gov Identifier: | NCT01933490 History of Changes |
| Other Study ID Numbers: | 1306M37181 |
| First Posted: | September 2, 2013 Key Record Dates |
| Last Update Posted: | November 1, 2019 |
| Last Verified: | October 2019 |

Keywords provided by University of Minnesota:
hyperinsulinemic hypoglycemia

DOCKET ALARM

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

**LAW FIRMS**
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

**FINANCIAL INSTITUTIONS**
Litigation and bankruptcy checks for companies and debtors.

**E-DISCOVERY AND LEGAL VENDORS**
Sync your system to PACER to automate legal marketing.